


Alpha Clinic Trial Test

Alpha Clinic Trials

Alpha Clinic ▲	Alpha Clinic Contact	Trial Sponsor	Disease Indication	Clinical Trial Name	Status of Enrollment	Learn More
City of Hope	Behnam Badie, MD (626) 256-4673 ext 60098 bbadie@coh.org	City of Hope	Cancer - Brain	Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma	Recruiting	
City of Hope	Nadia Ewing, MD (626) 256-4673 x89200 newing@coh.org	Sangamo Therapeutics	Hemophilia A	Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A	Recruiting	
City of Hope	Cheryl De Guzman 626-218-5613 CDeGuzman@coh.org	Children's Hospital Los Angeles	Infection After Stem Cell Transplant	Antiviral Cellular Therapy for Enhancing T-cell Reconstitution	Recruiting	
City of Hope	Alex Herrera, MD 626-218-2405 aherrera@coh.org	Kite Pharma	Cancer - Lymphoma	Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12)	Recruiting	
City of Hope	L. Elizabeth Budde, MD, PhD (626) 256-4673 ebudde@coh.org	City of Hope	Cancer - Leukemia	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Recruiting	
City of Hope	Hormoz Babaei Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Adaptimmune	Cancer - Myeloma	NY-ESO-1 ^{c259T} Alone and in Combination With Pembrolizumab for Multiple Myeloma	Recruiting	
City of Hope	Anthony Stein, MD 626-218-2405 stein@coh.org	Precision BioSciences, Inc.	Cancer - Lymphoma	Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL	Recruiting	
City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10 ^{c796T} in Subjects With Stage IIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)	Active, not recruiting	
City of Hope	Leslie Popplewell, MD 626-218-2405 lpopplew@coh.org	Novartis Pharmaceuticals	Cancer - Lymphoma	Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA)	Recruiting	

City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NSCLC)	Recruiting	
City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC	Recruiting	
City of Hope	Rie Miyahira 626-256-4673 ext 80032 rmiyahira@coh.org	Angiocrine Bioscience	Cancer - Leukemia	A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation	Recruiting	
City of Hope	Karen Reckamp, MD 626-218-9200 kreckamp@coh.org	Glaxo Smith Kline (GSK)	Cancer - Lung	Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab	Recruiting	
City of Hope	Mihaela Cristea, MD (626) 256-4673 x89200 mcristea@coh.org	Adaptimmune	Cancer - Ovarian	A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.	Recruiting	
City of Hope	Hormoz Babaei Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Celgene	Cancer - Lymphoma	An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM)	Recruiting	
City of Hope	Elizabeth Budde, MD 626-218-2405	Kite Pharma	Cancer - Lymphoma	A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma	Recruiting	
City of Hope	Myo Htut, MD 626-218-2405 mhtut@coh.org	Janssen Research & Development, LLC.	Cancer - Myeloma	A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)	Recruiting	
City of Hope	Warren Chow, MD (626) 256-4673 x89200 wchow@coh.org	Adaptimmune	Cancer - Sarcoma	A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma	Active, not recruiting	

City of Hope	Teresa Kim 626-218-0263 teresakim@coh.org	City of Hope	Sickle Cell Disease	A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant	Recruiting	
City of Hope	Tanya Dorff, MD 626-218-9200 tdorff@coh.org	City of Hope	Cancer - Prostate	PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer	Recruiting	
City of Hope	Nadia Ewing, MD (626) 256-4673 x89200 newing@coh.org	Sangamo Therapeutics	Hemophilia B	Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B	Recruiting	
City of Hope	Cara Nolan 626-218-3241 canolan@coh.org	Juno Therapeutics	Cancer - Lymphoma	An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)	Recruiting	
City of Hope	Elizabeth Budde, MD, PhD 626-218-2405 ebudde@coh.org	City of Hope	Cancer - Lymphoma	Angiocrine: HuVEC infusion post HCT in lymphoma (Budde)	Recruiting	
City of Hope	Erminia Massarelli, MD 626-218-9200 emassarelli@coh.org	Atara Bio.	Cancer - Nasopharyngeal Carcinoma	Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)	Recruiting	
UCSF	Romobia Hutchinson 415-476-9326 romobia.hutchinson@ucsf.edu	UCSF	Blood Disorder - Alpha Thalassemia Major	In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)	Recruiting	
UCSF	Julie DeCaris 510-428-3885 ext 2739 jdecaris@mailcho.org	Seattle Children's Hospital Foundation	Cancer - Leukemia	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	Recruiting	
UCSF	Cyrus Bascon 510-428-3885 ext 5396 CBascon@mailcho.org	bluebird bio	Sickle Cell Disease	A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease	Recruiting	
UCSF	Carol Fraser-Brown 415-476-2188 carolfraser-browne@ucsf.edu	Stanford University	Severe Combined Immunodeficiency (SCID)	AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients	Recruiting	
UCSF	Julie DeCaris 510-428-3885. ext.2739 jdecaris@mailcho.org	Bioerativ Therapeutics, Inc	Sickle Cell Disease	A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease	Recruiting	

UCSF & UCLA	<p>Marci Moriarty, BSN, RN 510-428-3885 ext 5396 mmoriarty@mailcho.org</p> <p>Bruck Habtemariam 310-794-0242 bhabtemariam@mednet.ucla.edu</p>	Sangamo Therapeutics	Blood Disorder - Beta-Thalassemia	A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)	Recruiting	
UC Davis	<p>Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu</p>	UC Davis	B-Cell Leukemia	A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies	Recruiting	
UC Davis	<p>Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu</p>	UC Davis	Eye - Retinopathy	Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy	Recruiting	
UC Davis & UCSD & UCSF	<p>Deborah Stewart 916-703-9118 distewart@ucdavis.edu</p>	UC Davis	HIV & Lymphoma	A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells	Recruiting	
UC Davis	<p>Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu</p>	Medeor Therapeutics	Kidney Transplant	Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants	Recruiting	
UC Davis	<p>Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu</p>	Pluristem Ltd.	Muscle Injury - hip fracture	Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty	Recruiting	
UC Davis	<p>Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu</p>	UC Davis	Cancer - Tongue Dysphagia	Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia	Recruiting	
UC Davis	<p>Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu</p>	Kite Pharma	Advanced Cancer	A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers	Recruiting	
UC Davis	<p>Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu</p>	Capricor Therapeutics	Muscle - Duchenne Muscular Dystrophy	A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)	Recruiting	
UC Davis	<p>Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu</p>	Atara Bio.	EBV-PTLD	Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)	Recruiting	

UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Nohla Therapeutics	Cancer – Leukemia	Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML	Recruiting	
UC Davis		Orca Biosystems, Inc.	Hematologic Malignancies	A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood, With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	UC Davis	Cancer - Lymphoma (HIV-Related)	Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant	Recruiting	

« first < previous 1 2

Source URL: https://www.cirm.ca.gov/our-progress/alpha-clinic-trial-test?order=field_alpha_clinic&sort=asc&page=1